Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C
Novel controlled attenuation parameter for noninvasive assessment of steatosis using Fibroscan®: validation in chronic hepatitis C
复制标题
DOI：
10.1111/j.1365-2893.2011.01534.x
复制
发表时间：
2012-04-01
影响因子：
2.5
通讯作者：
Beaugrand, M.
中科院分区：
文献类型：
--
作者：
Sasso, M.;Tengher-Barna, I.;Beaugrand, M.
． 一种新的控制衰减参数（CAP）被开发用于纤维扫描(R)评估肝脏脂肪变性，同时与肝脏硬度测量（LSM）。我们对慢性丙型肝炎（CHC）病毒患者的一大队列进行了CAP诊断准确性评估。共有615例CHC患者接受了纤维扫描(R)和肝活检，进行了分析。使用METAVIR评分对纤维化进行分级。脂肪变性目测分类为S0
. A novel controlled attenuation parameter (CAP) has been developed for Fibroscan (R) to assess liver steatosis, simultaneously with liver stiffness measurement (LSM). We assessed CAP diagnostic accuracy in a large cohort of patients with chronic hepatitis C (CHC) virus. A total of 615 patients with CHC, who underwent both Fibroscan (R) and liver biopsy, were analysed. Fibrosis was graded using METAVIR score. Steatosis was categorized by visual assessment as S0: steatosis in